Balyasny Asset Management
DGX icon

Balyasny Asset Management’s Quest Diagnostics DGX Stock Holding History

Balyasny Asset Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50,000
Closed -$5.72M – 1406
2020
Q3 		$5.72M Buy
+50,000
New +$5.91M 0.04% 564

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Balyasny Asset Management's DGX Position: Q1 2026 in Review

Balyasny Asset Management increased its Quest Diagnostics (DGX) stake by 71% in Q1 2026, buying an estimated $234K and bringing the position to 2,898 shares worth $568K. The position accounts for ﹤0.01% of the portfolio, ranked #2317.

Balyasny Asset Management first reported a position in DGX in Q2 2013 and has held it in 30 quarters since. The position peaked at $78.3M in Q2 2022. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Balyasny Asset Management held 2,898 shares of Quest Diagnostics worth $568K as of Q1 2026.
  • Balyasny Asset Management bought 1,203 Quest Diagnostics shares in Q1 2026, an estimated $234K.
  • Quest Diagnostics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2317 holding.
  • Balyasny Asset Management first reported a position in Quest Diagnostics in Q2 2013 and has held it in 30 quarters since.
  • Balyasny Asset Management's Quest Diagnostics position peaked at $78.3M in Q2 2022.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.